Multiple Sclerosis
Literature Review
How Does Cognitive Demand Affect Mobility in MS?
Patients with multiple sclerosis (MS) with an Expanded Disability Status Scale (EDSS) score between 4 and 6 have significantly slower times on the...
Audio
Thomas Edwards
Thomas Edwards discusses potential benefits of exercise in patients with MS with severe mobility disability.
From the Journals
Cognitive impairment in MS may affect fitness to drive motor vehicles
But impairment does not necessarily predict a road test failure.
Conference Coverage
What Therapy-Related Risks Can Patients With MS Tolerate?
NEW ORLEANS—Tolerance of risk related to current disease-modifying therapies (DMTs) on the part of patients with multiple sclerosis (MS) varies...
Conference Coverage
Is Chronic Migraine More Common in the MS Population?
BOSTON—At Island Neurological Associates in Plainview, New York, researchers uncovered a prevalence of chronic migraine among their population of...
Conference Coverage
Disease-Modifying Drug Treatment Before, During, and After Pregnancy in Women With MS
NEW ORLEANS—In a population of women with multiple sclerosis (MS) and a live birth, the rate of disease-modifying drug treatment decreased before...
Medical Education Library
News Briefs From the 2017 CMSC Annual Meeting
Neurology Reviews presents selected news highlights from the 31st Annual Meeting of the Consortium of MS Centers.
Medical Education Library
MS News From the AAN & CMSC Annual Meetings
BOSTON—In older people with multiple sclerosis (MS), fatigue and limited lower leg function are more common in people with MS...
Conference Coverage
Integrative approach to MS care underused, expert says
NEW ORLEANS – “There is a very evidence-based approach to integrative medicine. The core of it still is not familiar to a lot of physicians,” said...
Conference Coverage
Preliminary results promising from ublituximab phase II study for MS
NEW ORLEANS – The investigative agent ublituximab was well tolerated and demonstrated rapid B-cell depletion in relapsing multiple sclerosis.
Conference Coverage
Updated Analysis of Ocrelizumab’s Safety
NEW ORLEANS—The safety profile of ocrelizumab in ongoing open-label extension studies in relapsing multiple sclerosis (MS) and primary progressive...